Cost-benefit analysis when there's addiction

The Times reports on a kerfuffle over FDA cost-benefit analysis regarding smoking, in which a number of prominent economists have weighed in. A big bottom line for them: "Particularly when ... addiction occurs prior to the age of majority ... we find it inappropriate to measure the area under a demand curve to define welfare."